Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.31 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (late spermatids) | 0.10 |
| chemistry Open Targets | compounds already reach it: theophylline, oxtriphylline, namodenoson +5 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 2 Parkinson's papers of 146 | 0.85 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1184
Sealed predictions
- ADORA3 in dopamine neurons, braak+0.19 (p 0.623) → -0.40 (p 0.285)receipt 1189
Swarm cases
receipt 1189: ADORA3 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.754, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.722, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.901, n 18). could be the mix.
- skeptic
- leave-one-out range -0.23 to -0.02, sign flips 0; without severely affected donors -0.08 (p 0.754, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADORA3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts